Sodium Iodide (I123) Curium Netherlands

Sodium Iodide (123I) is a radiopharmaceutical used in nuclear medicine imaging. This sterile, non-pyrogenic solution aids in diagnostic procedures by detecting thyroid and other iodine-absorbing tissues. It is administered intravenously under medical supervision for accurate imaging results.

Sodium Iodide (123I) is primarily used for diagnostic imaging in nuclear medicine. It helps evaluate thyroid function and detect abnormalities such as nodules, goiter, or hyperthyroidism. The radiopharmaceutical is also used in whole-body scans to identify metastatic thyroid cancer or other iodine-absorbing tissues. Healthcare professionals rely on it for precise imaging in conditions requiring iodine uptake assessment.

After administration, Sodium Iodide (123I) is absorbed by iodine-avid tissues, emitting gamma radiation that is detected by imaging equipment. This process produces detailed images used to assess organ function and structure. Patients may experience mild discomfort at the injection site, but the radiopharmaceutical itself does not produce direct pharmacological effects.

Sodium Iodide (123I) should only be handled and administered by trained healthcare professionals in a controlled clinical setting. Pregnant or breastfeeding individuals should avoid exposure due to potential risks to the fetus or infant. Patients with known iodine allergies or impaired kidney function may require special consideration before administration.

Certain medications, such as thyroid hormones, antithyroid drugs, or iodine-containing supplements, may interfere with the uptake of Sodium Iodide (123I). Patients should disclose all current medications to their healthcare provider. Contrast agents used in other imaging procedures may also affect diagnostic accuracy.